MedTrace Logo

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).

Conditions

  • Sjogren's Disease

Interventions

DRUG

Administration of Lotemax

An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • James V Aquavella, MD · University of Rochester

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322528 on ClinicalTrials.gov